



October 21, 2021

Company name: RAKUS Co., Ltd.

Stock exchange listing: Tokyo

Stock code: 3923 URL <https://www.rakus.co.jp/en/>

Representative: Representative Director and President Takanori Nakamura

Inquiries: Director, Strategic Planning Department Yoshifumi Matsushima

Notice Regarding the Revision of Consolidated Guidance for Q2

RAKUS Co., Ltd. (hereinafter the "Company"), in light of recent business trends, decided at a board meeting held on October 21, 2021 to revise the guidance for Q2 the fiscal year ending March 2022 (from April 1, 2021 to September 30, 2021) which was disclosed at the earnings result on August 12, 2021 as follows:

1. Revision of Consolidated Guidance for Q2 (from April 1, 2021 to September 30, 2021)

	Sales	Operating profit	Ordinary profit	Profit attributable to owners of the parent company	Earnings per share
Previous guidance (A)	(million yen) 9,437	(million yen) 682	(million yen) 694	(million yen) 446	(yen) 2.46
Revised guidance (B)	9,473	888	898	587	3.24
Difference (B-A)	36	206	204	141	—
Difference (%)	0.4	30.2	29.5	31.8	—
(Reference) Earnings results of the previous fiscal year (FY 2021.3 Q2)	7,074	1,704	1,714	1,299	7.17

The Company conducted a two-for-1 stock split of common stock on October 1, 2020. EPS is calculated assuming that the stock split was conducted at the beginning of the fiscal year ended March 2020.

2. Reason of revision

Sales are expected to exceed the previous guidance mainly due to IT outsourcing business' strong performance. Profits are also expected to exceed the previous guidance driven by sales growth and decrease of expenses. Decrease of expenses is because personnel costs are expected to be smaller than the guidance due to a postponement in recruitment marketing activities and welfare expenses. Advertising costs and other expenses affected by the state of emergency are also expected not to be spent as budgeted.

(Note) The figures of revised guidance have been calculated based on the information currently available to the Company and certain assumptions which the Company deems reasonable. The actual results may differ from the guidance.

End